Page 74 - Read Online

Page 6 of 7 Ballestri et al. Metab Target Organ Damage 2023;3:13 https://dx.doi.org/10.20517/mtod.2023.21

Acquisition, analysis, or interpretation of data: Lonardo A , Ballestri S
Creation of figures of the manuscript: Ballestri S
Drafting and revising the work: Lonardo A , Ballestri S
Final approval of the manuscript: Lonardo A , Ballestri S

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and
future directions. Dig Liver Dis 2017;49:471-83. DOI PubMed
2. Wang D, Xu Y, Zhu Z, et al. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: a systematic
analysis of the global burden of disease study 2019. Front Nutr 2022;9:1047129. DOI PubMed PMC
3. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic
steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1. DOI
PubMed PMC
4. Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Explor Med. 2020:1:85-107.
10.37349/emed.2020.00007. DOI
5. Yoshizawa E, Yamada A. MRI-derived proton density fat fraction. J Med Ultrason (2001) 2021;48:497-506. DOI PubMed
6. Ladd ME, Bachert P, Meyerspeer M, et al. Pros and cons of ultra-high-field MRI/MRS for human application. Prog Nucl Magn Reson
Spectrosc 2018;109:1-50. DOI
7. Nelson SM, Hoskins JD, Lisanti C, Chaudhuri J. Ultrasound fatty liver indicator: a simple tool for differentiating steatosis from
nonalcoholic steatohepatitis: validity in the average obese population. J Ultrasound Med 2020;39:749-59. DOI PubMed
8. Radonjić T, Popović M, Zdravković M, et al. Point-of-care abdominal ultrasonography (POCUS) on the way to the right and rapid
diagnosis. Diagnostics 2022;12:2052. DOI PubMed PMC
9. Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is
correlated with metabolic parameters in NAFLD. Liver Int 2012;32:1242-52. DOI
10. Sourianarayanane A, McCullough AJ. Accuracy of ultrasonographic fatty liver index using point-of-care ultrasound in stratifying non-
alcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol 2023;35:654-61. DOI PubMed
11. Ballestri S, Nascimbeni F, Baldelli E, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/
histological parameters in various liver diseases. Metabolism 2017;72:57-65. DOI
12. Liu HK, Yang MC, Su YT, et al. Novel ultrasonographic fatty liver indicator can predict hepatitis in children with non-alcoholic fatty
liver disease. Front Pediatr 2018;6:416. DOI PubMed PMC
13. Xavier SA, Monteiro SO, Arieira CM, et al. US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score?
Mol Genet Metab 2021;132:204-9. DOI
14. Lonardo A, Ballestri S, Bedogni G, Bellentani S, Tiribelli C. The fatty liver index (FLI) 15 years later: a reappraisal. Metab Target
Organ Damage 2021;1:10. DOI
15. Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with
higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics 2021;11:98. DOI PubMed PMC